Minerva Neurosciences (NERV) CAO lists 1,683 shares and options
Rhea-AI Filing Summary
Minerva Neurosciences, Inc. (NERV) reported the initial holdings of Chief Accounting Officer Anthony Aliquo. He directly holds 1,683 shares of Common Stock.
He also holds several Employee Stock Options to acquire Common Stock, including options with exercise prices of $27.68 (expiring 2030-09-15) for 5,000 underlying shares and $6.33 (expiring 2032-02-15) for 8,750 underlying shares. Additional options include grants at $3.11 for 19,167 shares, $6.41 for 20,000 shares, $2.12 for 22,000 shares, $3.98 for 300,000 shares, and $4.84 for 150,000 shares, with expiration dates ranging from 2032-12-12 to 2036-05-31. Footnotes state that some options are fully vested and others vest 25% on specified initial dates, then in equal quarterly installments over three years.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Aliquo Anthony
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F6 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 524,917 shares (Direct);
Common Stock — 1,683 shares (Direct)
Footnotes (6)
- F1. Fully vested.
- F2. The option vested 25% on December 13, 2023 and then vests or vested in equal quarterly installments over 3 years thereafter.
- F3. The option vested 25% on October 4, 2024 and then vests or vested in equal quarterly installments over 3 years thereafter.
- F4. The option vested 25% on December 5, 2025 and then vests or vested in equal quarterly installments over 3 years thereafter.
- F5. The option vests 25% on December 22, 2026 and then in equal quarterly installments over 3 years thereafter.
- F6. The option vests 25% on June 1, 2027 and then in equal quarterly installments over 3 years thereafter.
Key Figures
Direct Common Stock holding: 1,683 shares
Stock option exercise price: $27.68 per share
Underlying shares for option at $27.68: 5,000 shares
+4 more
7 metrics
Direct Common Stock holding
1,683 shares
Directly owned Common Stock reported for Anthony Aliquo
Stock option exercise price
$27.68 per share
Employee Stock Option expiring 2030-09-15 over 5,000 underlying shares
Underlying shares for option at $27.68
5,000 shares
Employee Stock Option (right to buy) with $27.68 exercise price
Stock option exercise price
$6.33 per share
Employee Stock Option expiring 2032-02-15 over 8,750 underlying shares
Underlying shares for option at $6.33
8,750 shares
Employee Stock Option (right to buy) with $6.33 exercise price
Largest option grant underlying shares
300,000 shares
Employee Stock Option with $3.98 exercise price expiring 2035-12-21
Option exercise price
$4.84 per share
Employee Stock Option over 150,000 underlying shares expiring 2036-05-31
Key Terms
Employee Stock Option (right to buy), exercise price, expiration date, vests or vested in equal quarterly installments, +1 more
5 terms
Employee Stock Option (right to buy) financial
"security_title": "Employee Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "27.6800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2030-09-15""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests or vested in equal quarterly installments financial
"then vests or vested in equal quarterly installments over 3 years thereafter."
fully vested financial
"Fully vested."
FAQ
What does Form 3 reveal about Minerva Neurosciences (NERV) officer Anthony Aliquo’s stock ownership?
The Form 3 shows Anthony Aliquo, Chief Accounting Officer, directly holds 1,683 shares of Common Stock of Minerva Neurosciences, Inc., plus multiple Employee Stock Options over additional Common Stock at specified exercise prices and expiration dates.
What are the key stock option positions disclosed for NERV officer Anthony Aliquo?
Disclosed Employee Stock Options include rights to acquire 5,000 shares at $27.68 (expiring 2030-09-15) and 8,750 shares at $6.33 (expiring 2032-02-15), plus additional options at exercise prices of $3.11, $6.41, $2.12, $3.98, and $4.84 over specified underlying share amounts.
Are Anthony Aliquo’s NERV stock options vested or unvested?
Some options are described as fully vested, while others vest 25% on specified initial dates and then vest or vested in equal quarterly installments over three years. One option vests 25% on December 22, 2026 and another 25% on June 1, 2027, each with three-year quarterly vesting thereafter.
Do the reported NERV holdings involve any recent purchases or sales by Anthony Aliquo?
The Form 3 lists holdings only. It reports Anthony Aliquo’s existing Common Stock and Employee Stock Option positions as of the filing, without any coded purchase (P) or sale (S) transactions in this data.
What are the latest expiration dates of Anthony Aliquo’s NERV stock options?
The reported Employee Stock Options have expiration dates ranging from 2030-09-15 to 2036-05-31. The grant with a $4.84 exercise price for 150,000 underlying shares expires on 2036-05-31.
AI-generated analysis. How Rhea-AI works. Not financial advice.
